Combination of Anlotinib and PD-1/PD-L1 Inhibitors as Second-line and Subsequent Therapy in Advanced Small-cell Lung Cancer

被引：0
|
作者：
Yu, L. [1 ]
Xu, J. [1 ]
Qiao, R. [1 ]
Zhong, H. [1 ]
Han, B. [1 ]
Zhong, R. [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
small-cell lung cancer; anlotinib; PD-1/PD-L1;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.01-10
引用
收藏
页码：S391 / S392
页数：2
相关论文
共 50 条
  • [41] PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer
    Shankar, Bairavi
    Naidoo, Jarushka
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S4034 - S4037
  • [42] Research progression of PD-1/PD-L1 in non-small cell lung cancer
    Xing Liu
    Xiaodong Xie
    Oncology and Translational Medicine, 2017, 3 (03) : 111 - 115
  • [43] Targeting the PD-1/PD-L1 axis in non-small cell lung cancer
    Kumar, Rajiv
    Collins, Dearbhaile
    Dolly, Saoirse
    McDonald, Fiona
    O'Brien, Mary E. R.
    Yap, Timothy A.
    CURRENT PROBLEMS IN CANCER, 2017, 41 (02) : 111 - 124
  • [44] Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer
    Rocco, Danilo
    Malapelle, Umberto
    Del Re, Marzia
    Della Gravara, Luigi
    Pepe, Francesco
    Danesi, Romano
    Troncone, Giancarlo
    Gridelli, Cesare
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2020, 16 (02) : 87 - 96
  • [45] Efficiency of PD-1 and PD-L1 Inhibitors in Malignant Therapy
    Gappa, Birgit
    Kobold, Sebastian
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2019, 144 (01) : 7 - 8
  • [46] Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer
    Miyawaki, Taichi
    Naito, Tateaki
    Yabe, Michitoshi
    Kodama, Hiroaki
    Nishioka, Naoya
    Miyawaki, Eriko
    Mamesaya, Nobuaki
    Kobayashi, Haruki
    Omori, Shota
    Wakuda, Kazushige
    Ono, Akira
    Kenmotsu, Hirotsugu
    Murakami, Haruyasu
    Mori, Keita
    Harada, Hideyuki
    Takahashi, Kazuhisa
    Takahashi, Toshiaki
    SUPPORTIVE CARE IN CANCER, 2022, 30 (02) : 1633 - 1641
  • [47] PD-1 inhibitors-based second-line therapy for metastatic gastric cancer
    Gou, Miaomiao
    Zhang, Yong
    Wang, Zhikuan
    Dai, Guanghai
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [48] PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
    Katerina Ancevski Hunter
    Mark A. Socinski
    Liza C. Villaruz
    Molecular Diagnosis & Therapy, 2018, 22 : 1 - 10
  • [49] iSEND is an algorithmic model specific for advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors
    Park, Wungki
    Florou, Vaia
    Algaze, Sandra
    Saravia, Diana
    Kwon, Deukwoo
    Lopes, Gilberto
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [50] Clinical benefit of PD-1/PD-L1 inhibitors for poor performance status patients with advanced non-small cell lung cancer
    Koyama, Junji
    Morise, Masahiro
    Tanaka, Ichidai
    Hori, Sho
    Matsuzawa, Reiko
    Ozone, Sachiko
    Matsushita, Akihiro
    Matsuo, Masaki
    Asano, Shuichi
    Tanaka, Taro
    Shima, Koichiro
    Kimura, Tomoki
    Sakamoto, Koji
    Kondoh, Yasuhiro
    Hashimoto, Naozumi
    JOURNAL OF CHEMOTHERAPY, 2025,
12345